Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Revance Therapeutics (RVNC)

Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 381,023
  • Shares Outstanding, K 104,390
  • Annual Sales, $ 234,040 K
  • Annual Income, $ -323,990 K
  • EBIT $ -165 M
  • EBITDA $ -62 M
  • 60-Month Beta 0.90
  • Price/Sales 1.37
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.89
  • Most Recent Earnings $-0.37 on 11/07/24
  • Next Earnings Date 02/26/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.31
  • Number of Estimates 2
  • High Estimate -0.28
  • Low Estimate -0.34
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.23 +13.00%
on 01/10/25
3.70 -1.35%
on 01/17/25
+0.56 (+18.12%)
since 01/03/25
3-Month
3.01 +21.26%
on 12/09/24
5.97 -38.86%
on 11/06/24
-2.19 (-37.50%)
since 11/05/24
52-Week
2.30 +58.70%
on 06/26/24
7.56 -51.72%
on 03/01/24
-1.45 (-28.43%)
since 02/05/24

Most Recent Stories

More News
Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyperhidrosis -

DRMAW : 0.0224 (+15.46%)
DRMA : 1.2400 (+5.08%)
RVNC : 3.65 (+0.27%)
Revance Therapeutics Stock’s Retail Sentiment Muted Even As Teoxane Makes Better Offer Than Crown Labs

The offer represents a 16% premium over the $3.10-per-share agreement with Crown Laboratories announced last month.

RVNC : 3.65 (+0.27%)
Revance Therapeutics Stock Plummets To 4-Month Low As Crown Labs Halves Takeover Offer: Retail Fumes

The price cut follows a notice received by Revance in September alleging violations of an exclusive distribution agreement with Teoxane.

RVNC : 3.65 (+0.27%)
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?

The big pharma company's top drug is losing ground, but its dividend keeps rising.

CVS : 67.05 (-2.32%)
UNH : 516.85 (+1.09%)
ABT : 126.34 (-0.35%)
CI : 316.65 (-1.47%)
AZN : 74.93 (-2.08%)
BGNE : 184.71 (+0.49%)
RVNC : 3.65 (+0.27%)
ABBV : 210.01 (-0.92%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such...

RVNC : 3.65 (+0.27%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such...

RVNC : 3.65 (+0.27%)
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023

Revance Therapeutics, Inc. (RVNC), today announced that the company will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of market. Revance will host a corresponding...

RVNC : 3.65 (+0.27%)
Revance to Participate in the Needham 22nd Annual Healthcare Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), today announced that the company will participate in the 22 nd Annual Needham Virtual Healthcare Conference, taking place April 17 – 20, 2023. Chief Financial...

RVNC : 3.65 (+0.27%)
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report

Revance Therapeutics, Inc. (RVNC), today announced the release of its 2022 ESG Report, detailing the company’s progress towards its ESG priorities of innovation and access, workplace culture and strong...

RVNC : 3.65 (+0.27%)
Revance to Participate in Upcoming Investor Conferences

Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the following investor conferences.

RVNC : 3.65 (+0.27%)

Business Summary

Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS' peptide technology, which when combined...

See More

Key Turning Points

3rd Resistance Point 3.67
2nd Resistance Point 3.66
1st Resistance Point 3.66
Last Price 3.65
1st Support Level 3.65
2nd Support Level 3.64
3rd Support Level 3.64

See More

52-Week High 7.56
Fibonacci 61.8% 5.55
Fibonacci 50% 4.93
Fibonacci 38.2% 4.31
Last Price 3.65
52-Week Low 2.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar